Fabienne Mackay

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Sangamo Therapeutics UK Ltd. researches and develops transcription factors in the regulation of genes. The company was founded on April 21, 1999 and is headquartered in Cheltenham, the United Kingdom.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne.

Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom.

Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia.

Uniseed Management Pty Ltd. (Uniseed) is an independent Australian venture capital firm which was founded in 2000. The firm headquartered in Australia.

Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia.

Cortical Pty Ltd. discovers and develops medical drugs for the treatment of inflammatory and proliferative diseases. The company was founded in 2003 by Eric F. Morand and Magdy N. Iskander and is headquartered in Clayton, Australia.

Fibrotech Therapeutics Pty Ltd develops novel drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as kidney disease, chronic heart failure, pulmonary fibrosis, and arthritis. The company was founded by Richard Ernest Gilbert, Darren James Kelly, Spencer J Williams, Steven C Zammit, David Stapleton, Henry Krum and Yuan Zhang in 2006 and is headquartered in Melbourne, Australia.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Great Ormond Street Hospital Children's Charity is a non-profit organization which engages in fundraising and charitable activities to help children's who have medical needs. The company was founded in 1998 and is headquartered in London, the United Kingdom.

Otifex Therapeutics Pty Ltd. develops treatment for ear diseases. The company was founded by Burkhard Franz and Colin Anderson in 2009 and is headquartered in Melbourne, Australia.

Nexgen Plants Pty Ltd. develops anti-viral technology solutions that enables virus resistant plant varieties to be developed for major food, fibre, energy and ornamental crops. The company was founded in 2013 and is headquartered in St. Lucia, Australia.

d3 Medicine LLC develops drugs and medicines. It is strategic advisory company focused on developing medicines for use in indications including infectious diseases, oncology, and inflammation. The company was founded by Craig Rayner in 2012 and is headquartered in Parsippany, NJ.

OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.

Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom.

Solvanix Pty Ltd. develops novel therapy for improving stability and reducing the aggregation of fully human antibodies. The company was founded by Daniel Christ in 2014 and is headquartered in Darlinghurst, Australia.